AMD News – LCTX Stock Priced Increased Over 10% Pre-Market: Why It Happened
- The stock price of Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) increased by over 10% pre-market. This is why it happened.
The stock price of Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) – a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions – increased by over 10% pre-market. This appears to be continued momentum from earlier this week when the company announced that a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) had recently been treated with its lead product candidate OpRegen at Hadassah-Hebrew University Medical Center in Jerusalem, using a named patient compassionate use approval granted by the Israeli Ministry of Health.Apple-converted-space”>
OpRegen is an investigational cell therapy – which consists of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space and is currently being investigated in a 24-patient phase 1/2a clinical trial for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
This patient had presented to the Department of Ophthalmology at Hadassah-Hebrew University Medical Center in late December 2020 with sudden and severe visual acuity decreases in one eye. And BCVA in the worse vision eye was measured at 20/200, compared to 20/40 in the patient’s contralateral eye. After an onset of blurred vision in 2018, evaluation and imaging diagnosed the patient as suffering from AVMD.Apple-converted-space”>
Because AVMD is known as a disease of impaired RPE function leading to atrophy and shares similar characteristics to dry AMD, the team at Hadassah approached Lineage about the potential to treat this patient on a compassionate use basis. And lineage submitted a request on behalf of Hadassah-Hebrew University Medical Center which was approved by the Israeli Ministry of Health.Apple-converted-space”>
Following approval from the University’s Ethics Committee, the patient was treated in February 2021. And the delivery of OpRegen RPE cells via pars plana vitrectomy was successful, with no complications arising during the procedure and the patient remains in follow-up.
“Lineage is pioneering a new branch of medicine, consisting of the directed differentiation and transplant of specific cell types to replace damaged or dying cells with the goal of restoring or improving function lost to injury or disease. With OpRegen, we are transplanting new retina cells to replace old cells that were lost or damaged to disease, with a goal of providing stability or functional improvements to vision. As outlined more fully on our recent earnings call, we believe there are many potential applications of Lineage’s core technology and intend this year to demonstrate that although we currently have three clinical-stage product candidates, those assets and our underlying platform may have utility in additional settings. For example, our RPE cells may be useful for treating additional retinal diseases, such as AVMD or Stargardt’s Disease. Similarly, our spinal cord program may be applicable to other conditions characterized by demyelination, and our oncology platform may have application across many different tumor types, depending on which antigen we elect to present to the patient’s immune system.”
“In this first instance, we treated a patient with AVMD, because it closely resembles dry AMD and similarly involves impaired RPE function and progressive vision loss. When the team at Hadassah approached us about treating their existing AVMD patient with OpRegen on a compassionate use basis, we were supportive of the request and saw it as an opportunity to investigate a new application for our OpRegen product candidate.”
— Brian M. Culley, Lineage CEO
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.